Tafamidis—A Pricey Therapy for a Not-So-Rare Condition
- 1 March 2020
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 5 (3), 247-248
- https://doi.org/10.1001/jamacardio.2019.5233
Abstract
The Viewpoint highlights the high price of treatment with tafamidis for people with transthyretin amyloidosis in the United States.Keywords
This publication has 5 references indexed in Scilit:
- Novel Therapies for an Aging PopulationJAMA, 2019
- Tafamidis Treatment for Patients with Transthyretin Amyloid CardiomyopathyNew England Journal of Medicine, 2018
- Nonbiopsy Diagnosis of Cardiac Transthyretin AmyloidosisCell Metabolism, 2016
- Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fractionEuropean Heart Journal, 2015
- ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice GuidelinesCell Metabolism, 2014